Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (191-200 of 238) with videos related to

Pageof 24
Sort By:
Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancersKristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
Elife|February 2, 2017
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancerElsa B Krall, Belinda Wang, Diana M Munoz, et al.
Cancer Cell|July 7, 2007
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapyDanan Li, Takeshi Shimamura, Hongbin Ji, et al.
Cell Reports|December 16, 2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P Kodack, Anna F Farago, Anahita Dastur, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2012
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Kadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.
Cancer Discovery|October 10, 2019
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast CancerCarlotta Costa, Ye Wang, Amy Ly, et al.
Nature Medicine|October 3, 2018
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemiaElena J Orlando, Xia Han, Catherine Tribouley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
Characteristics of lung cancers harboring NRAS mutationsKadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven TumorsKelli-Ann Monaco, Scott Delach, Jing Yuan, et al.
Pageof 24

Showing results (191-200 of 238) with videos related to

Sort By:
Pageof 24
Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancersKristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
Elife|February 2, 2017
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancerElsa B Krall, Belinda Wang, Diana M Munoz, et al.
Cancer Cell|July 7, 2007
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapyDanan Li, Takeshi Shimamura, Hongbin Ji, et al.
Cell Reports|December 16, 2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient CareDavid P Kodack, Anna F Farago, Anahita Dastur, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2012
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Kadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.
Cancer Discovery|October 10, 2019
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast CancerCarlotta Costa, Ye Wang, Amy Ly, et al.
Nature Medicine|October 3, 2018
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemiaElena J Orlando, Xia Han, Catherine Tribouley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
Characteristics of lung cancers harboring NRAS mutationsKadoaki Ohashi, Lecia V Sequist, Maria E Arcila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven TumorsKelli-Ann Monaco, Scott Delach, Jing Yuan, et al.
Pageof 24